Effect of contrast dose on diagnostic performance in DCE-MR breast imaging
- PMID: 33089949
- PMCID: PMC7701107
- DOI: 10.1002/acm2.13010
Effect of contrast dose on diagnostic performance in DCE-MR breast imaging
Abstract
Objective: To assess the diagnostic performance of breast magnetic resonance (MR) imaging as a function of gadolinium contrast dose using a retrospective reader study.
Material and methods: IRB approval was obtained prior to the start of this study and was HIPAA compliant. One-hundred and fifty MR breast examinations were included that were acquired between January 2001 and December 2006. Seventy-five patients received contrast doses (gadopentetate dimeglumine) by weight of 0.10 mmol/kg and 75 patients were imaged using fixed volumes of 20 ml. The images were assessed by two radiologists with performance calculated for each reader as well as a combined assessment. Dose response was measured by comparing performance between cases binned by dose: <=0.10; >0.10; and >0.13 mmol/kg. Statistical significance was calculated using a one-sided Z-test for differences in proportions with interobserver agreement calculated using Cohen's kappa statistics.
Results: In the combined reader assessment with equivocal lesions classified as negative, sensitivity rose from 66% (19/29) to 92% (24/26, P < 0.01) and 95% (18/19, P < 0.01) with the specificity also increasing from 65% (32/49) to 87% (40/46, P < 0.01) and 86% (32/37, P = 0.01) corresponding to doses <=0.10, >0.10, >0.13 mmol/kg. With equivocal lesions classified as positive, sensitivity rose from 79% (23/29) to 92% (24/26, P < 0.10) and 95% (18/19, P < 0.10) Specificity also increased from 53% (26/49) to 72% (33/46, P < 0.05) and 70% (26/37, P = 0.05) with increasing dose. Interobserver agreement also improved at the higher doses.
Keywords: breast; contrast dose; diagnostic performance; magnetic resonance imaging.
© 2020 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.
Conflict of interest statement
None of the authors has any conflict of interest. There is no industry support for this project.
Figures


Similar articles
-
Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.Invest Radiol. 2009 Feb;44(2):95-104. doi: 10.1097/RLI.0b013e3181911eab. Invest Radiol. 2009. PMID: 19077911 Clinical Trial.
-
Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine.Radiology. 2005 Oct;237(1):45-56. doi: 10.1148/radiol.2371041369. Epub 2005 Aug 26. Radiology. 2005. PMID: 16126926 Clinical Trial.
-
Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for Breast MR imaging (DETECT Trial).Radiology. 2011 Feb;258(2):396-408. doi: 10.1148/radiol.10100968. Epub 2010 Dec 16. Radiology. 2011. PMID: 21163915 Clinical Trial.
-
Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.AJR Am J Roentgenol. 2003 Sep;181(3):663-76. doi: 10.2214/ajr.181.3.1810663. AJR Am J Roentgenol. 2003. PMID: 12933457 Clinical Trial.
-
Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention.J Neurosurg. 2007 Apr;106(4):557-66. doi: 10.3171/jns.2007.106.4.557. J Neurosurg. 2007. PMID: 17432704 Clinical Trial.
Cited by
-
Effect of contrast agent on T2-weighted fat-suppressed imaging and diffusion-weighted imaging in the diagnosis of breast tumors.Quant Imaging Med Surg. 2024 May 1;14(5):3655-3664. doi: 10.21037/qims-23-1700. Epub 2024 Apr 10. Quant Imaging Med Surg. 2024. PMID: 38720833 Free PMC article.
References
-
- ACR Practice Parameter For The Performance of Contrast Enhanced Magnetic Resonance Imaging (MRI) of The Breast. (n.d.). Retrieved from https://www.acr.org/‐/media/ACR/Files/Practice‐Parameters/mr‐contrast‐br...
-
- Heywang‐Köbrunner SH, Haustein J, Pohl C, et al. Contrast‐enhanced MR imaging of the breast: comparison of two different doses of gadopentetate dimeglumine. Radiology. 1994;191:639–646. - PubMed
-
- Jansen SA, Fan X, Yang C, et al. Relating dose of contrast media administered to uptake and washout of malignant lesions on DCEMRI of the breast. Acad Radiol. 2010;17:24–30. - PubMed
-
- Knopp MV, Bourne MW, Sardanelli F, et al. Gadobenate dimeglumine‐enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. AJR Am J Roentgenol. 2003;181:663–676. - PubMed
-
- Kuhl CK. Current status of breast MR imaging. Part 2. Clinical applications. Radiology. 2007;244:672–691. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources